Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage.
Measles incidence, vaccine efficacy, and mortality were examined prospectively in two districts in Bissau where vaccine coverage for children aged 12-23 months was 81% (Bandim 1) and 61% (Bandim 2). There was little difference in cumulative measles incidence before 9 months of age (6.1% and 7.6%, respectively). Between 9 months and 2 years of age, however, 6.1% contracted measles in Bandim 1 and 13.7% in Bandim 2. Even adjusting for vaccination status, incidence was significantly higher in Bandim 2 (relative risk 1.6, P = .04). Even though 95% of the children had measles antibodies after vaccination, vaccine efficacy was not more than 68% (95% confidence interval [CI] 39%-84%) and was unrelated to age at vaccination. Unvaccinated children had a mortality hazard ratio of 3.0 compared with vaccinated children (P = .002), indicating a protective efficacy against death of 66% (CI 32%-83%) of measles vaccination. These data suggest that it will be necessary to vaccinate before age 9 months to control measles in hyperendemic urban African areas.
Aaby
P
P
Institute of Anthropology, University of Copenhagen, Denmark.
Knudsen
K
K
Jensen
T G
TG
Thårup
J
J
Poulsen
A
A
Sodemann
M
M
da Silva
M C
MC
Whittle
H
H
D000367:Age Factors; D000914:Antibodies, Viral / Q000032:analysis; D015331:Cohort Studies; D006169:Guinea-Bissau / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D008457:Measles / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality; D008458:Measles Vaccine / Q000276:immunology; D008459:Measles virus / Q000276:immunology; D011446:Prospective Studies; D012044:Regression Analysis; D014505:Urban Population; D014611:Vaccination
D000914:Antibodies, Viral; D008458:Measles Vaccine